We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Announcing a new article publication for BIO Integration journal. Diabetes, a common metabolic condition, poses a substantial health burden worldwide. To revolutionize diabetes management, enhance ...

Today, Plantsulin blends this century-old discovery with modern scientific validation to offer a fast, convenient "whole-body ...

Glp-1 Analogues Market OverviewThe Glp analogues market size is expected to be worth USD 606.3 billion by 2034.The target market was valued at USD 45.3 billion in 2024.The market is projected to grow ...

Here's your chance to suggest an article for Andy's consideration that could be included in this best of 2024 listing. Each day of the 12 Days of Christmas gets one entry added for each month of ...

Unlike a regular smartwatch, which displays everything on a full-color screen, a hybrid smartwatch hides the tech behind a classic analog watch face. As such, hybrids retain the traditional watch ...

This strategic investment reflects our commitment to responsible investing, addressing critical global healthcare challenges like the growing need for insulin analogues. Moreover, it strengthens ...

Laboratory of Medicinal Chemistry, Department of Chemistry and Life Science, School of Advanced Engineering, Kogakuin University, 2665-1 Nakano-machi, Hachi-oji, Tokyo 192-0015, Japan ...

"This strategic investment reflects our commitment to responsible investing, addressing critical global healthcare challenges like the growing need for insulin analogues," said Bakheet Al Katheeri, ...

This strategic investment reflects our commitment to responsible investing, addressing critical global healthcare challenges like the growing need for insulin analogues. Moreover, it strengthens ...

Many drugs, including insulin, essentially became free. But the American Rescue Plan made a major change that hit drug companies with even larger penalties for raising prices. In January 2024 ...